Navigation Links
Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
Date:12/8/2008

SAN DIEGO, Dec. 8 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that Roche has dosed the first patient in a Phase 1 pharmacokinetic clinical trial with a subcutaneous formulation using Enhanze Technology of a biologic directed to a Roche exclusive target. This has triggered a milestone payment under the agreement.

Roche has also selected an additional exclusive target under the existing license and collaboration agreement. Under the terms of the agreement, Roche will pay Halozyme for exclusive, global rights for the application of its hyaluronidase enzyme, rHuPH20, to a fourth biologic target selected by Roche.

"Roche and Halozyme have successfully completed the necessary drug product formulation and preclinical studies required to initiate a clinical trial. Entering the clinic is a significant achievement and demonstrates Roche's strong commitment to a successful partnership," said Jonathan Lim, M.D., Halozyme's President and CEO. "We are very pleased with the progress that is being made through our collaboration. Roche is a global leader in the development of biologics and we are excited that they have selected a fourth exclusive target, in addition to the three already under development, further validating Halozyme's core technology."

Roche has also maintained its rights to other targets covered in the license and collaboration agreement. An aggregate payment of $10.25 million will be made to Halozyme for commencing a Phase 1 clinical trial, exercising exclusive global rights to a fourth biologic target and for annual maintenance fees.

Halozyme also announced that it has entered into a supply agreement with Roche to provide rHuPH20 for use in formu
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
2. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
3. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
6. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
7. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
8. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
9. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
10. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
11. Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... TAMPA, Fla. , Jan. 23, 2015  iMD Companies, Inc. ... plan to increase market share and grab a foothold in ... with influence, production capabilities and a presence in the sector, ... them facilitate the growth of hemp and medical marijuana, iMD ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... Directors has approved a share repurchase program. The open-ended ... million of Mallinckrodt plc ordinary shares. ... remain top priorities as we continue to pursue a ...
(Date:1/22/2015)... BOULDER, Colo. , Jan. 22, 2015  BiOptix is ... Klakamp as Vice President of Chemistry and Biochemistry. Scott ... Takeda Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course ... and development. "Scott is a nationally recognized ...
Breaking Medicine Technology:iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... YONKERS, N.Y., Sept. 27, 2011 As a result ... that could be dangerous to their health, according to ... Americans who currently take a prescription medicine told pollsters ... a doctor,s visit or medical procedure, declining tests, or ...
... Pa., Sept. 27, 2011 Inovio Pharmaceuticals, Inc. (NYSE ... development of synthetic immunogens against cancers and infectious diseases, ... Research and Development Agreement (CRADA) with the United States ... Plum Island Animal Disease Center. This collaboration will evaluate ...
Cached Medicine Technology:Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 2Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 3Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 4Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 5Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 2Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 3Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 4
(Date:1/22/2015)... LunaDress, with its top dressmaking technologies, has ... the business is showing its latest designs of wedding dresses ... to the company’s CEO, all the fresh new products are ... discounts, up to 80% off. All the clothes from LunaDress ...
(Date:1/22/2015)... AZ (PRWEB) January 22, 2015 Padre Murphy's ... long supporter of Pro Player Health Alliance (PPHA). ... Padre Murphy's in getting everyone, including NFL greats, treated for ... of the leading groups supporting the cause in the valley. ...
(Date:1/22/2015)... 22, 2015 Blue Cross and Blue Shield ... exemplify what it means to “Live Fearless.” , ... to share their stories about how they or someone they ... others by living in the moment. By telling these types ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
(Date:1/22/2015)... released a new blog post presenting the basic features of ... an accidental death and dismemberment rider for a car insurance ... benefits if the insured dies in an accident. Accidental death ... insurance. , AD&D is not expensive and can be ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... Sleep Patterns (CRSP), a new self-report measure of childrens ... children, may be a reliable and valid self-report measure ... children eight to 12 years of age, according to ... at SLEEP 2008, the 22nd Annual Meeting of the ...
... June 11 DaVita Inc., a leading,provider of ... kidney,failure and disease (CKD), recently announced that Debbie ... for DaVita(R) and Mary,Burgess, RD, Grant Program Manager ... five abstracts at the XIV International Congress on,Nutrition ...
... Cancer Survivors, and Introduces Women,s Empowerment Bracelet in ... Asia, Strides Made To ... ... Ambassador, Reese,Witherspoon visited Japan to bring a message of empowerment and hope to the,Asia Pacific ...
... DALLAS June 11, 2008 Children in U.S. ... multiple disparities in health care, a UT Southwestern Medical ... in June,s online issue of Pediatrics , Dr. ... lead author, used statistics from the National Survey of ...
... Sears and His Team of Physicians Give Manuel ... Uribe A New Lease on Life, DANVERS, Mass., ... the heaviest living man in the world, has,lost more than one-third of his ... of doctors led by Dr. Barry Sears,creator of the Zone Diet. As he ...
... Chain Was First to Go Smokefree, Says Ban Is ... Eat,n Park Restaurants,( http://www.eatnpark.com ), Pennsylvania,s largest family ... in favor of the bill,that bans smoking in many ... to sign the bill., In May 2007, Eat,n ...
Cached Medicine News:Health News:'Children's Report of Sleep Patterns' a reliable, maybe a valid measure of children's sleep habits 2Health News:DaVita Dietitians to Speak at the International Congress on Nutrition and Metabolism in Renal Disease in France 2Health News:Avon Global Ambassador Reese Witherspoon Visits Japan for First Time in Historic Role 2Health News:Avon Global Ambassador Reese Witherspoon Visits Japan for First Time in Historic Role 3Health News:Avon Global Ambassador Reese Witherspoon Visits Japan for First Time in Historic Role 4Health News:Children in non-English-speaking households face many health disparities, researcher concludes 2Health News:Video: World's Heaviest Man Celebrates Birthday and Weight Loss Milestone 2Health News:Video: World's Heaviest Man Celebrates Birthday and Weight Loss Milestone 3Health News:Eat'n Park Restaurants - State's Largest Family Dining Chain - Congratulates Pennsylvania House and Senate for Passing Smoking Ban 2
... U.S. and international engineering and design ... and Plating System* provides seamless integration ... use for open reduction internal fixational ... system works well beyond the standard, ...
... Conforming to U.S. and international engineering ... TC-100 Screw and Plating System* provides ... ease of use for open reduction ... the TC-100 system works well beyond ...
... The CARDIA PDA Closure Device has been ... Patent Ductus Arteriosus. Introduced through standard venous ... and reliable method for the percutaneous closure ... from 2mm-10mm within the ductus.,An integral locking ...
Half pin skeletal traction pins with cove point....
Medicine Products: